New Once-Daily drug could simplify Wilson's disease treatment
NCT ID NCT07465718
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This Phase 3 trial compares a new once-daily formulation of trientine tetrahydrochloride (TETA 4HCl) to the standard drug D-penicillamine for people newly diagnosed with Wilson's disease. About 38 adults and children (ages 8 and up, weighing at least 55 lbs) will be randomly assigned to one of the two treatments for 48 weeks. The study aims to see if the new pill is safe and effective at controlling copper levels in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trientine tetrahydrochloride (TETA 4HCl)
- What this could lead to
- If it works, this could offer a simpler once-daily treatment option for Wilson's disease, potentially improving adherence and quality of life.
- What could go wrong
- This is a small Phase 3 trial with only 38 participants, so results may not apply to everyone. The new drug may not be as effective as the standard treatment, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing Friendship Hospital,Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, 100000, China
-
Children's Hospital & Institute of Child Health
Lahore, 54000, Pakistan
-
King Faisal Specialist Hospital and Research Center
Riyadh, 11211, Saudi Arabia
-
PIMS Hospital
Islamabad, 44000, Pakistan
-
Shifa International Hospital
Islamabad, Pakistan
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhengjiang Province, 310009, China
-
University of Colorado Anschutz School of Medicine
Denver, Colorado, 80045, United States
-
University of Michigan Medical Centre
Ann Arbor, Michigan, 48109-2029, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a global patient registry unlock the mysteries of Wilson's disease?
- Can a single infusion rewrite the genetic code behind wilson disease?
- Gene therapy could free Wilson's patients from daily pills
- New blood tests could simplify Wilson's disease monitoring
- One-Time gene shot aims to tame rare copper disorder